Inhibikase Therapeutics Inc., a clinical-stage pharmaceutical company focused on pulmonary arterial hypertension (PAH), has appointed Timothy Pigot as Chief Commercial and Strategy Officer. Pigot brings over 30 years of experience in the pharmaceutical industry, having previously served as Chief Commercial Officer at Aerovate Therapeutics and Vice President of Marketing at MyoKardia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.